Enveric Biosciences, Inc. (ENVB)
| Market Cap | 9.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -50.25M |
| Shares Out | 52.68M |
| EPS (ttm) | -1.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,379,105 |
| Open | 0.200 |
| Previous Close | 0.200 |
| Day's Range | 0.182 - 0.220 |
| 52-Week Range | 0.170 - 3.740 |
| Beta | 5.73 |
| Analysts | Buy |
| Price Target | 0.66 (+262.6%) |
| Earnings Date | Aug 12, 2022 |
About ENVB
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida. [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for ENVB stock is "Buy." The 12-month stock price forecast is 0.66, which is an increase of 262.64% from the latest price.
News
Enveric Biosciences to Participate in Upcoming Conferences in June 2022
NAPLES, Fla. , June 8, 2022 /PRNewswire/ - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-ins...
Enveric Biosciences to Participate in the Microdose Psychedelic Capital Conference on May 26, 2022
NAPLES, FLA , May 24, 2022 /PRNewswire/ - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-insp...
Enveric Biosciences to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022
NAPLES, Fla. , May 17, 2022 /PRNewswire/ - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-ins...
Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline to Shareholders
The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psychedelic-inspired treatments and the other developing innovative cannabinoid treat...
Enveric Biosciences to Host Fireside Chat with Dr. Bob Dagher, Chief Medical Officer, on May 17th at 10:00 a.m. ET
NAPLES, FL , May 5, 2022 /PRNewswire/ - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspir...
Enveric Biosciences Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
NAPLES, Fla. , May 3, 2022 /PRNewswire/ - Enveric Biosciences Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspi...
Enveric Biosciences to Participate in Upcoming Investor Conferences in April 2022
NAPLES, Fla. , April 6, 2022 /PRNewswire/ - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-in...
Enveric Biosciences Reports Full-Year 2021 Financial Results and Provides Business Update
NAPLES, Fla. , March 31, 2022 /PRNewswire/ - Enveric Biosciences Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-in...
Enveric Biosciences Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application
NAPLES, Fla., March 29, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience company developing next-generation, psychedelic-inspired mental health medic...
Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates
Patent Applications Aim to Expand Opportunities for Novel Therapeutics to Address a Broad Range of Psychiatric and Neurological Disorders NAPLES, Fla., March 15, 2022 /PRNewswire/ - Enveric...
Enveric Biosciences to Participate in Upcoming Investor Conferences in March 2022
NAPLES, Fla. , March 3, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a cutting-edge neuroscience company developing next-generation, psychedelic-inspired mental h...
Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules
NAPLES, Fla., March 1, 2022 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused pharmaceutical company developing next-generation, psychedelic-inspi...
Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Re...
Clinical trial aim is to include the identification and characterization of the Cancer Related Distress symptoms most responsive to psychedelic-associated therapy NAPLES, Fla., Feb. 17, 2022 /PRNewswire...
Enveric Biosciences Closes $10 Million Public Offering
Psychedelics-based company Enveric Biosciences (NASDAQ:ENVB) has closed its previously announced underwritten public offering of 20 million shares of its common stock and warrants to purchase up to 20 m...
Enveric Biosciences Announces Closing of $10 Million Public Offering
NAPLES, Fla. , Feb. 15, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience company developing next-generation, psychedelic-inspired mental health and onc...
Enveric Biosciences Shares Fall After $10M Equity Raise
Enveric Biosciences Inc (NASDAQ: ENVB) has priced its previously announced underwritten public offering of 20 million shares and warrants to purchase up to 20 million shares at a combined price of $0.50...
Enveric Biosciences Announces Pricing of $10 Million Public Offering
NAPLES, Fla. , Feb. 11, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience company developing next-generation, psychedelic-inspired mental health and onc...
Enveric Biosciences Files Provisional Patent For CBD+Celecoxib Conjugate For Osteoarthritis
Psychedelics-based neuroscience company Enveric Biosciences (NASDAQ: ENVB) announced the development of EV104a and EV104b, new molecular conjugates for Osteoarthritis and other pain indications. EV104a ...
Enveric Biosciences Announces Successful Synthesis and Filing of Provisional Patent for EV104 - Cannabinoid + Celecox...
Target Indications include Osteoarthritis and Other Pain Conditions NAPLES, Fla. , Feb. 8, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience company dev...
Enveric Biosciences to Participate in Upcoming Investor Conferences in February 2022
NAPLES, Fla. , Jan. 27, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology...
Enveric Biosciences CEO, Dr. Joseph Tucker, Provides 2021 Year in Review and 2022 Outlook in Letter to Shareholders
NAPLES, Fla. , Jan. 18, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company, today released a letter to shareholders from Dr....
Enveric Biosciences to Participate in the H.C. Wainwright BioConnect Conference on January 10-13, 2022
NAPLES, Fla., Jan. 6, 2022 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology ...
Enveric Biosciences Appoints Dr. Bob Dagher as Chief Medical Officer
NAPLES, Fla., Dec. 6, 2021 /PRNewswire/ -- Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology ...
Enveric Biosciences to Participate in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference on December 6th
NAPLES, Fla., Nov. 29, 2021 /PRNewswire/ - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a patient-centric biotechnology company developing next-generation mental health and oncology...
Enveric Biosciences' CBD-Based Product Reduces Dermatitis Severity In Animal Study
Enveric Biosciences (NASDAQ: ENVB) announced data from a preclinical rodent model evaluating EV102, the company's cannabidiol (CBD) based product in development for the topical treatment of radiodermati...